Previous studies have demonstrated that CXCL2 plays an important role in anti-tumor drug resistance on various types of cancer, including breast cancer, colorectal cancer and glioblastoma [30–32], and modulates the property of migration, invasion and apoptosis in cancer cells [33, 34]. Here, CXCL2 is linked to breast carcinoma.